证券简称：康缘药业 证券代码：600557 公告编号：2025-030 江苏康缘药业股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）根据上海证券交易所发布 的《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关要求， 现将公司 2025 年半年度主要经营数据披露如下： 一、2025 年 1-6 月公司主营业务分行业、分产品、分地区经营情况 单位：元 币种：人民币 | | | | 主营业务分行业情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利 率（%） | 营业收入 比上年同 期增减 | 营业成本 比上年同 期增减 | 毛利率比上年同期 增减（%） | | | | | | （%） | （%） | | | 工业销售 | 1,623,380,051.40 | 467,008,495.59 | 71.23 | ...

杭州天目山药业股份有限公司 章 程 （2025年 8月修订） （尚需提交2025 年第三次临时股东大会审议） 二〇二五年八月 目 录 杭州天目山药业股份有限公司章程 …………………………………………………… 第 1 页 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公 司 的组 织和 行 为， 根 据《 中华 人 民共 和 国公 司法 》 （以 下 简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司章程指引》《上海证券交易所股票上市规则》 和其他有关规定，制定本章程。 第二条 公 司 1989 年 10 月 31 日 经 临 安 县 人 民 政 府 临 政 发 〔1989〕18 号文件批准，作为临安市首家国有企业股份制试点单位， 由杭州天目山药厂发起并认购部分股份和向社会公开募集股份而设 立股份制企业；1992 年根据国家体改委发布的《股份有限公司规范 意见》进行规范；1993 年又根据《公司法》进行了重新规范；公司 依法在浙江省市场监督管理局注册登记，取得营业执照，统一社会 信用代码：91330000253930812T。 第三条 公司于 1989 ...

陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日取得 陕西省药品监督管理局换发的《药品生产许可证》 （许可证编号：陕 20160073）， 换发后的《药品生产许可证》有效期至 2030 年 8 月 24 日，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：陕西康惠制药股份有限公司 证券代码：603139 证券简称：康惠制药 公告编号：2025-052 陕西康惠制药股份有限公司 关于换发药品生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 生产负责人：郭建刚 许可证编号：陕 20160073 社会信用代码：916100006984144239 分类码：AhzCz 注册地址：陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人：王延岭 企业负责人：王延岭 质量负责人：郝红梅 质量授权人：郝红梅 有效期至：2030 年 8 月 24 日 生产地址和生产范围： 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号：膏药，软膏剂，茶 剂，颗粒剂，硬胶囊剂，片剂，酒剂，合剂，搽 ...

Group 1 - The stock price of Kanghui Pharmaceutical closed at 22.36 yuan on July 30, down by 0.34 yuan, representing a decline of 1.50% [1] - The trading volume on that day was 23,694 hands, with a total transaction amount of 0.53 billion yuan [1] - Kanghui Pharmaceutical focuses on the research, production, and sales of traditional Chinese medicine, with products including tablets, hard capsules, and granules [1] Group 2 - On July 30, the company announced it would provide a joint liability guarantee of 5 million yuan to its subsidiary Sichuan Chunsheng Pharmaceutical for loan renewal, maintaining a guarantee balance of 28.9 million yuan before and after the guarantee [1] - On the same day, the net outflow of main funds was 317.61 thousand yuan, accounting for 0.14% of the circulating market value [1]

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].

Core Points - The company is Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd, established in 1993 and registered in Jilin Province, China [4][6][7] - The company aims to build a health industry chain and ecosystem, contributing to the modernization and internationalization of the national health industry while maximizing shareholder returns [9] - The registered capital of the company is RMB 966,494,707 [7] Chapter Summaries Chapter 1: General Principles - The company is established to protect the rights of shareholders, employees, and creditors, following the Company Law and Securities Law of the People's Republic of China [4] - The company has undergone several changes in its registration and licensing, including a name change to Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd in 2000 [6][7] Chapter 2: Business Objectives and Scope - The business objectives include serving human health and contributing to the health industry [9] - The business scope includes manufacturing various pharmaceutical forms, research and development of traditional Chinese medicine, and medical project investments [9] Chapter 3: Shares - The company issues shares in the form of stocks, with a total of 966,494,707 shares issued, all being ordinary shares [10][21] - The company follows principles of fairness and transparency in share issuance [10] Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights to dividends, attend meetings, and supervise company operations [16] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [25] Chapter 5: Board of Directors - The board of directors is responsible for the company's management and must act in the best interest of the company and its shareholders [18] - The company has provisions for independent directors and committees within the board [18] Chapter 6: Senior Management - Senior management includes the general manager, deputy general managers, and other key personnel [8] Chapter 7: Financial Accounting System, Profit Distribution, and Auditing - The company must adhere to a financial accounting system and undergo internal audits [8] Chapter 8: Notices and Announcements - The company is required to issue notices and announcements as per legal requirements [8] Chapter 9: Mergers, Divisions, Capital Increases, Reductions, Dissolution, and Liquidation - The company can merge, divide, increase or reduce capital, and dissolve according to legal procedures [8] Chapter 10: Amendments to the Articles - The company can amend its articles of association following the prescribed procedures [8] Chapter 11: Supplementary Provisions - The articles of association serve as a binding document for the company, shareholders, directors, and senior management [8]

Core Viewpoint - The announcement from the Shanxi Provincial Drug Administration details the results of GMP compliance inspections for 14 pharmaceutical manufacturing companies, indicating their adherence to national drug production standards [2]. Group 1: Inspection Results - The inspection results include companies such as China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., which was inspected for hard capsule production of penicillin oral preparations [3]. - Other companies listed include Shanxi Huida Pharmaceutical Co., Ltd. and Shanxi Zhongyuan Pharmaceutical Co., Ltd., with various products ranging from oral solutions to traditional Chinese medicine pieces being evaluated for compliance [3][4]. - The inspections were conducted between January 16 and March 31, 2025, with all companies listed achieving compliance [3][4]. Group 2: Compliance Details - The compliance checks were based on the Drug Administration Law of the People's Republic of China and related regulations, ensuring that the inspected companies meet the required quality management standards [2]. - Specific products inspected include oral solutions, hard capsules, and raw materials, with detailed addresses and production lines provided for each company [3][4]. - The results signify a commitment to maintaining high standards in pharmaceutical production within the region, which is crucial for public health and safety [2].

Core Points - GuangYuYuan Chinese Herbal Medicine Co., Ltd. is a publicly listed company established in accordance with the Company Law of the People's Republic of China, with a registered capital of RMB 489,491,141 [2][3] - The company aims to innovate and inherit traditional Chinese medicine culture, contributing to the health of the Chinese people [4] - The company has a comprehensive business scope that includes the production, sales, and research of various traditional and Western medicine forms [4] Company Structure - The company is governed by a board of directors, with the chairman serving as the legal representative [3] - The company has established a party committee and a disciplinary committee to ensure adherence to the leadership of the Communist Party of China [1] - The company has a total of 489,491,141 shares issued, all of which are ordinary shares [5] Share Issuance and Management - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for all shares of the same category [4][5] - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [6][7] - The company is prohibited from acquiring its own shares, except under specific circumstances approved by the shareholders' meeting [6][7] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and the ability to supervise the company's operations [11] - Shareholders are required to comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [16][40] - The company must maintain transparency and disclose information regarding significant events and shareholder rights [13][17] Governance and Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [48][49] - Shareholder proposals must be submitted in advance, and the company is required to notify shareholders of meeting details [58][59] - Voting at shareholder meetings can be conducted in person or by proxy, with specific rules governing the validity of votes [66][67]

Group 1 - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][3] - The registered capital of the company is RMB 491,855,896 [3] - The company was approved by the China Securities Regulatory Commission to issue 17 million shares of ordinary stock to the public in 2009 [2][3] Group 2 - The company's business scope includes the production and sale of large-volume injections, small-volume injections, tablets, granules, and raw materials [4][5] - The company aims to leverage its technological advantages and high-tech talent resources to provide high-quality pharmaceutical products and services [4] Group 3 - The company has a share structure consisting of ordinary shares, with a total of 491,855,896 shares issued [8] - The shares are issued at a par value of RMB 1 per share [8] Group 4 - The company’s shareholders have the right to receive dividends and participate in decision-making processes at the shareholders' meetings [12][13] - Shareholders holding more than 5% of the shares are subject to specific trading restrictions [10][11] Group 5 - The company’s board of directors is responsible for major decisions, and shareholders have the right to request the convening of shareholder meetings under certain conditions [20][23] - The company must disclose information regarding significant transactions and decisions to ensure transparency [42][43]

General Information - Chongqing Pharscin Pharmaceutical Co., Ltd. was established as a joint-stock company in accordance with the Company Law of the People's Republic of China [2] - The company was registered with the Chongqing Market Supervision Administration and obtained its business license on September 22, 2017, with a registered capital of RMB 417.596314 million [2][3] - The company issued 40.06 million shares to the public and was listed on the Shenzhen Stock Exchange on October 20, 2017 [2][3] Company Structure - The company is a permanent joint-stock company, with the chairman serving as the legal representative [3] - The legal representative's civil activities conducted on behalf of the company will have legal consequences for the company [3] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [3] Management and Governance - Senior management includes the general manager, deputy general managers, financial officer, and board secretary [4] - The company has established a party organization in accordance with the Communist Party of China regulations, which plays a leading role in governance [4] Business Objectives and Scope - The company's business objective is to promote national medicine and provide quality healthcare products [4] - The business scope includes the production of various pharmaceutical forms, including injections, tablets, and traditional Chinese medicine, as well as related consulting and technology transfer services [4][5] Share Issuance and Capital Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued at the establishment was 300 million, with a par value of RMB 1 per share [6] - The company has a total of 417.596314 million shares issued, all of which are ordinary shares [6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company governance [12] - Shareholders must comply with laws and the company's articles of association, and they are liable for their subscribed capital [40] - The company has provisions for shareholders to request the convening of a general meeting under certain conditions [52][57] Corporate Governance and Decision-Making - The general meeting of shareholders is the company's authority, responsible for electing directors and approving major corporate actions [46] - The company must hold an annual general meeting within six months after the end of the fiscal year [51] - Decisions regarding significant transactions and capital changes require shareholder approval [47][50] Financial Management and Investment - The company is required to disclose financial information and adhere to regulations regarding financial assistance and investments [21][49] - The company can engage in financial investments within approved limits and must disclose significant financial activities [48][49]